MA39421A - Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes - Google Patents
Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantesInfo
- Publication number
- MA39421A MA39421A MA039421A MA39421A MA39421A MA 39421 A MA39421 A MA 39421A MA 039421 A MA039421 A MA 039421A MA 39421 A MA39421 A MA 39421A MA 39421 A MA39421 A MA 39421A
- Authority
- MA
- Morocco
- Prior art keywords
- sub
- relates
- peptides
- gastrointestinal tract
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 3
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 102100020903 Ezrin Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108010055671 ezrin Proteins 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4735—Villin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
<!--startfragment-->la présente invention concerne le domaine de la médecine, en particulier le domaine de l'industrie chimique et pharmaceutique et concerne des peptides dérivés de l'ezrine, en particulier un peptide comprenant une séquence d'acides aminés de formule générale (i) x<sub>1</sub> ekkrretvere x<sub>2</sub>x<sub>3</sub>, dans laquelle chaque x représente un résidu d'acide aminé non polaire. L'invention concerne l'utilisation de ces peptides en tant qu'agents immunostimulants et, plus spécifiquement, pour une utilisation dans le traitement et la prévention d'infections antivirales, antibactériennes et antifongiques et le traitement de maladies du tractus gastro-intestinal, en particulier les troubles ulcératifs du tractus gastro-intestinal. La présente invention concerne également des compositions pharmaceutiques comprenant les peptides. En outre, l'invention concerne des procédés de traitement d'une infection et de maladies ulcératives du tractus gastro-intestinal, consistant à administrer les peptides à des patients qui en ont besoin.<!--endfragment-->
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015120667 | 2015-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39421A true MA39421A (fr) | 2017-07-19 |
Family
ID=56117690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039421A MA39421A (fr) | 2015-06-01 | 2016-06-01 | Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9682140B2 (fr) |
| EP (1) | EP3191504B1 (fr) |
| JP (1) | JP6721419B2 (fr) |
| KR (1) | KR101842978B1 (fr) |
| CN (1) | CN106188267B (fr) |
| AU (1) | AU2016203656B2 (fr) |
| CA (1) | CA2931875C (fr) |
| CY (1) | CY1120501T1 (fr) |
| DK (1) | DK3191504T3 (fr) |
| ES (1) | ES2660894T3 (fr) |
| GB (1) | GB2546439B (fr) |
| HR (1) | HRP20180560T1 (fr) |
| HU (1) | HUE038737T2 (fr) |
| LT (1) | LT3191504T (fr) |
| MA (1) | MA39421A (fr) |
| MD (1) | MD3191504T2 (fr) |
| ME (1) | ME03033B (fr) |
| MX (1) | MX377333B (fr) |
| PL (1) | PL3191504T3 (fr) |
| PT (1) | PT3191504T (fr) |
| RS (1) | RS57067B1 (fr) |
| SG (1) | SG10201604401UA (fr) |
| SI (1) | SI3191504T1 (fr) |
| SM (1) | SMT201800190T1 (fr) |
| WO (1) | WO2016193285A1 (fr) |
| ZA (1) | ZA201603723B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| CN106596977B (zh) * | 2017-02-08 | 2018-06-08 | 南京医科大学第一附属医院 | ezrin在制备哮喘诊断试剂中的应用 |
| WO2021198346A2 (fr) | 2020-04-01 | 2021-10-07 | Dr. Nesselhut Besitzgesellschaft Mbh | Peptide ezrine 1 destiné à être utilisé dans un procédé de traitement de la covid-19 |
| EP4125996B1 (fr) * | 2020-04-01 | 2024-08-28 | Pantapharm AG | Peptide ezrine 1 destiné à être utilisé dans un procédé de traitement de la covid-19 |
| AU2022247001A1 (en) | 2021-03-31 | 2023-10-05 | Pantapharm Ag | Ezrin peptide 1 for use in a method of treating post covid-19 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2290293A (en) | 1994-06-08 | 1995-12-20 | Rupert Donald Holms | Preparation which inhibits the autoimmune response in HIV, or SLE, patients |
| GB2354241A (en) * | 1999-09-17 | 2001-03-21 | Rupert Donald Holms | Regulatory/unfolding peptides of ezrin |
| GB0301879D0 (en) | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| WO2007060440A2 (fr) | 2005-11-23 | 2007-05-31 | Regent Research L.L.P. | Utilisation de peptides dans une thérapie anti-ulcère |
-
2016
- 2016-06-01 EP EP16728271.4A patent/EP3191504B1/fr active Active
- 2016-06-01 MA MA039421A patent/MA39421A/fr unknown
- 2016-06-01 RS RS20180392A patent/RS57067B1/sr unknown
- 2016-06-01 MX MX2016007122A patent/MX377333B/es active IP Right Grant
- 2016-06-01 SG SG10201604401UA patent/SG10201604401UA/en unknown
- 2016-06-01 US US15/170,362 patent/US9682140B2/en active Active
- 2016-06-01 GB GB1705990.8A patent/GB2546439B/en not_active Expired - Fee Related
- 2016-06-01 ES ES16728271.4T patent/ES2660894T3/es active Active
- 2016-06-01 WO PCT/EP2016/062336 patent/WO2016193285A1/fr not_active Ceased
- 2016-06-01 MD MDE20170043T patent/MD3191504T2/ro not_active IP Right Cessation
- 2016-06-01 KR KR1020160068187A patent/KR101842978B1/ko not_active Expired - Fee Related
- 2016-06-01 HR HRP20180560TT patent/HRP20180560T1/hr unknown
- 2016-06-01 AU AU2016203656A patent/AU2016203656B2/en not_active Ceased
- 2016-06-01 LT LTEP16728271.4T patent/LT3191504T/lt unknown
- 2016-06-01 PT PT167282714T patent/PT3191504T/pt unknown
- 2016-06-01 ZA ZA2016/03723A patent/ZA201603723B/en unknown
- 2016-06-01 JP JP2016110444A patent/JP6721419B2/ja not_active Expired - Fee Related
- 2016-06-01 SM SM20180190T patent/SMT201800190T1/it unknown
- 2016-06-01 CA CA2931875A patent/CA2931875C/fr active Active
- 2016-06-01 HU HUE16728271A patent/HUE038737T2/hu unknown
- 2016-06-01 ME MEP-2018-96A patent/ME03033B/fr unknown
- 2016-06-01 DK DK16728271.4T patent/DK3191504T3/en active
- 2016-06-01 CN CN201610384013.2A patent/CN106188267B/zh active Active
- 2016-06-01 PL PL16728271T patent/PL3191504T3/pl unknown
- 2016-06-01 SI SI201630027T patent/SI3191504T1/en unknown
-
2018
- 2018-03-26 CY CY20181100335T patent/CY1120501T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39421A (fr) | Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA40769B1 (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| EP2548552A3 (fr) | Ensemble de titration pour 1-amino-alkylcyclohexanes | |
| CN106456583A (zh) | 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合 | |
| WO2011151722A3 (fr) | Méthodes et compositions de traitement pharmaceutique par voie orale | |
| IL265761B2 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| MA63861A1 (fr) | Composition pharmaceutique de virus non enveloppé | |
| MA63248B1 (fr) | Formulations d'un inhibiteur de la kallicréine plasmatique | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA47082B1 (fr) | Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1 | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
| MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
| WO2025038987A3 (fr) | Agents de dégradation de protéine pde4, compositions pharmaceutiques et applications thérapeutiques | |
| MA54276B1 (fr) | Montélukast destinée au traitement de l'arthrose de la main | |
| MA58507A1 (fr) | Composition pharmaceutique aqueuse de levilimab | |
| MA29329B1 (fr) | Derives d'amide en tant que ligands de canal ionique, compositions pharmaceutiques et methodes d'utilisation associees | |
| EP3804708A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de l'allodynie provoquée par des médicaments anticancéreux | |
| EP3782702A1 (fr) | Compositions et leur utilisation pour le traitement de maladies infectieuses et du cancer | |
| MA43793B1 (fr) | Procédé de préparation de formulations solides de mésalazine | |
| EA202091320A1 (ru) | Местное применение диоксидина при инфекционно-воспалительных поражениях эпителия |